Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $105.31 and last traded at $105.14, with a volume of 872612 shares trading hands. The stock had previously closed at $98.82.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. BTIG Research reissued a "buy" rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Monday, July 13th. UBS Group upped their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a "buy" rating in a research note on Wednesday, July 1st. Leerink Partners set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, April 30th. Wedbush set a $165.00 price objective on shares of Oruka Therapeutics in a research report on Monday, April 27th. Finally, Weiss Ratings upgraded shares of Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, July 15th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $134.30.

Check Out Our Latest Research Report on Oruka Therapeutics

Oruka Therapeutics Stock Performance

The firm has a market capitalization of $6.34 billion, a P/E ratio of -54.20 and a beta of -0.34. The firm has a 50-day moving average of $83.59 and a 200-day moving average of $60.75.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, research analysts forecast that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $58.97, for a total value of $6,191,850.00. Following the completion of the sale, the director directly owned 73,743 shares in the company, valued at approximately $4,348,624.71. This trade represents a 58.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,290 shares of the business's stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $59.07, for a total value of $607,830.30. Following the completion of the transaction, the senior vice president directly owned 16,406 shares of the company's stock, valued at approximately $969,102.42. This trade represents a 38.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 188,406 shares of company stock valued at $12,019,683. Company insiders own 23.49% of the company's stock.

Institutional Trading of Oruka Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc purchased a new position in shares of Oruka Therapeutics during the second quarter valued at approximately $28,000. BNP Paribas Financial Markets boosted its holdings in Oruka Therapeutics by 464.0% in the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock worth $31,000 after purchasing an additional 2,306 shares during the last quarter. Royal Bank of Canada boosted its holdings in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after purchasing an additional 365 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in Oruka Therapeutics in the 4th quarter worth approximately $37,000. Finally, PNC Financial Services Group Inc. purchased a new stake in Oruka Therapeutics during the 3rd quarter valued at $39,000. Hedge funds and other institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Company Profile

(Get Free Report)

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

See Also

• Five stocks we like better than Oruka Therapeutics
• SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
• 3 Dividend Champion Utilities for a Market That Can't Sit Still
• These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
• First Solar’s Profit Engine Faces a New Policy Test in Washington

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Oruka Therapeutics Right Now?

Before you consider Oruka Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.

While Oruka Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here